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Can a Thoracic Surgeon Identify Lymph Node Metastases
during Surgery Based on Their Size?
Analysis of 844 Metastatic and 10,462 Nonmetastatic Lymph Nodes
Ryuichi Suemitsu, MD, PhD,* Sadanori Takeo, MD, PhD,* Hironori Matsuzawa, MD,*
Masafumi Yamaguchi, MD, PhD,* Seiya Momosaki, MD, PhD,† and Noriko Uesugi, MD, PhD†
Objective: A metastatic lymph node commonly becomes enlarge;
however, there is limited data available with regard to the direct mea-
surement of lymph nodes and their clinicopathologic characteristics.
Methods: The size of dissected lymph node was quantified in a total
of 848 nodes with metastasis and 10,462 nodes without metastasis
from 454 patients with lung cancer who underwent a pulmonary
resection with lymph node dissection.
Results: The short axis and the volume of the metastatic lymph
nodes were significantly greater than those of the nonmetastatic
ones. The smaller the lymph node, the less frequently the lymph
nodes were metastatic; however, the ratios of nodes smaller than the
fifth largest lymph node with metastasis of adenocarcinoma and
squamous cell carcinoma were 21.8 to 26.2%, respectively. When
the hilar and mediastinal lymph node stations were examined, 1.14
to 4.00% of the lung cancer patients had lymph node metastasis in
small lymph node despite having no metastases in the largest and
second largest lymph nodes.
Conclusions: The small lymph nodes in the hilar or mediastinal
stations frequently had metastases of carcinoma even though largest
and second largest lymph nodes were negative for metastases,
especially in adenocarcinoma cases. Surgical oncologists should,
therefore, perform systemic lymph node dissection, and not sam-
pling, during a pulmonary resection of lung cancer.
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Generally, the lymph nodes become enlarged because ofmetastasis of carcinoma. Preoperative N-staging is de-
termined by clinicopathologic findings, including chest com-
puted tomography (CT), endoscopic ultrasound-guided fine-
needle aspiration (EUS-FNA), positron emission tomography
(PET), and mediastinoscopy.1–5 However, these examinations
may yield false-negative assessments: CT, 81.1%1; EUS-
FNA, 20 to 25.3%2,5; PET, 25 to 57%1,3; and video-assisted
mediastinoscopic lymphadenectomy, 0.9%.4 In addition, the
direct assessment of nodal staging during surgery results in
only 11% false- positive and 9% false-negative assessments.6
This investigation analyzed a large quantity of dissected
lymph nodes by direct measurements.
PATIENTS AND METHODS
Patients
From August 1994 to December 2006, 869 patients
underwent a surgical resection for lung cancer at the Depart-
ment of Thoracic Surgery, National Hospital Organization,
Kyushu Medical Center. Of these patients, 454 with adeno-
carcinoma (AC), squamous cell carcinoma (SQ), bronchi-
oloalveolar carcinoma, adenosquamous cell carcinoma, large
cell carcinoma, or small cell carcinoma who underwent a
pulmonary resection with lymph node dissection were en-
rolled, whereas those patients who had multiple primary
lesions, underwent an contralateral nodal dissection, received
neoadjuvant chemotherapy, or had another histologic type of
tumor were excluded, and cases with insufficient data were
also excluded. The study population included 312 men
(68.7%) and 142 women (31.3%) ranging in age from 28 to
90 years (average, 66.5 years). The diagnosis was confirmed
by a histologic analysis of the resected specimen and based
on the criteria of the World Health Organization.7 The his-
tologic types were AC in 257 patients (56.6%), SQ in 132
(29.1%), bronchioloalveolar carcinoma in 26 (5.7%), adeno-
squamous cell carcinoma in 17 (3.7%), small cell carcinoma
in 14 (3.1%), and large cell carcinoma in 8 (1.8%). The
pathologic and clinical staging was based on the International
Union Against Cancer, tumor, node, metastasis-classification,
6th editions,8 and we also performed brain CT, bone scintig-
raphy, and abdominal CT to determine clinical staging. The
pathologic stage defined as stage IA/IB in 120 (26.4%)/103
(22.7%) patients, stage IIA/IIB in 12 (2.6%)/34 (7.5%) patients,
stage IIIA/IIIB in 84 (18.5%)/62 (13.7%) patients, and stage IV
in 39 patients (8.6%) and clinical stage defined as stage IA/IB in
170 (37.4%)/121 (26.7%) patients, stage IIA/IIB in 12 (2.6%)/29
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(6.4%) patients, stage IIIA/IIIB in 58 (12.8%)/34 (7.5%) pa-
tients, and stage IV in 30 patients (6.6%). The primary cancer
lesions were in the right upper lobe in 155 patients (34.1%), right
middle lobe in 24 (5.3%), right lower lobe in 105 (23.1%), left
upper lobe in 106 (23.3%), and left lower lobe in 64 (14.1%).
Surgical Method
The operations included 403 lobectomies (88.8%),
16 bilobectomies (3.5%), 19 pneumonectomies (4.2%), 5
extra pleural pneumonectomies (1.1%), 8 segmental resec-
tions (1.8%), and 3 wedge resections (2.7%). A systemic
nodal dissection was performed in principle; however,
nodal sampling was indicated for poor-risk cases, includ-
ing patients with advanced age, poor performance status,
low pulmonary function, and low cardiac function, as well
as for those with a small, pure ground-glass opacity lesion.
In 47 of 454 patients (10.4%), nodal sampling was indi-
cated. An indication for clinical stage IIIA was nonbulky
N2, and an indication for clinical stage IV was resectable
metastatic lesions with a single organ such as brain and
adrenal. As for clinical stage IIIB, in cases presenting with
mediastinal invasions, we had actively performed surgery
if complete resection was possible.
Measurement of the Size of the Lymph Node
and Definition of Station
The short-, median-, and long-axis diameters of all
lymph nodes from fresh resected pulmonary tissue were
measured by a direct assessment. The lymph node measure-
ments were done by the surgeons. The volume of the lymph
node was defined as the imaginary elliptic content and cal-
culated as follows: (short-axis diameter)  (middle-axis di-
ameter)  (long-axis diameter)  /6 mm3. The lymph node
stations were defined by the lymph node map of Naruke et
al.,9 as approved by The Japan Lung Cancer Society.
Statistical Analysis
The statistical significance of the data was determined
by Student t test or 2 tests. The data are presented as the
means  SD. The receiver operating characteristic (ROC)
curves were generated for the short-axis diameter and the
volume of lymph nodes with AC and SQ by plotting the
sensitivity versus 1  specificity. The area under the curve
(AUC) was calculated for each ROC curve.10,11 The p values
of less than 0.05 were considered to be significant.
RESULTS
A total of 11,306 hilar and mediastinal lymph nodes
were resected from 454 patients, and the mean number of
lymph nodes examined per patient was 24.9. Of these, 844
lymph nodes had metastasis and 10,462 did not. Table 1
shows the distribution of the short axis of the lymph nodes
in each station. All stations of the metastatic lymph node
were significantly larger than those of the nonmetastatic
ones. The long-axis diameter results were identical to the
short-axis diameter (data not shown). The mean short- and
long-axis diameters of the lymph nodes with metastasis was
6.8  3.9 mm and 13.2  8.4 mm, respectively, which was
significantly greater than that of those without metastasis
(4.2  2.1 mm; p  0.0001, 8.6  5.7 mm; p  0.0001,
respectively). When quantified the mean volume of lymph
node with or without metastasis, the volume of lymph nodes
with metastasis was significantly greater than that of without
metastasis (Table 2). An ROC analysis of AC and SQ is
shown in Figure 1. The AUC for the short-axis diameter of
AC and SQ were 0.727 and 0.785, respectively (Figure 1A),
whereas the AUC for the volume of AC and SQ were 0.540
and 0.761, respectively (Figure 1B).
The ranking of the size of lymph nodes with metastasis of
AC and SQ is shown in Figure 2. In this table, patients who
underwent a dissection of more than six lymph nodes included
248 patients with AC and 123 patients with SQ. Based on the
short-axis diameter and the volume, the largest lymph node
contained metastases in 27.4% and 21.8% of AC and 25.0% and
25.0% in SQ, respectively, and these ratios had a tendency to
decrease according to a decrease in the size of the lymph nodes,
and these tendencies were the same with the long-axis diameter
(data not shown). Specifically, when the largest and second
largest lymph nodes had no metastasis, the ratio of metastasis in
smaller than the third largest lymph nodes was as follows: the
short-axis diameter, 6.0% in AC and 7.3% in SQ; the long-axis
diameter, 11.3% in AC and 11.4% in SQ (data not shown); and
the volume, 11.3% in AC and 11.4% in SQ. When divided into
lymph node station by each lobe, mediastinal lymph node
metastasis was detected in 1.87 to 3.03% of patients, with
metastasis of the third largest or less and without metastasis of
the first and second largest, in mediastinal stations: 3 and 4 of the
TABLE 1. Lymph Node Nomenclature and the Size of
Dissected Lymph Nodes with and without Metastasis in Each
Lymph Node Station
Station
Short-Axis Diameter (mm)
Positive LNs
(n)
Negative LNs
(n) p
Mediastinal lymph nodes
1 Highest mediastinal 5.7  3.6 (70) 3.6  1.8 (1217) 0.0001
2 Paratracheal 5.9  2.7 (15) 3.7  1.7 (259) 0.0001
3 Pretracheal 8.1  5.4 (83) 4.2  2.1 (1265) 0.0001
3a Anterior mediastinal 6.5  3.4 (30) 3.6  1.6 (207) 0.0001
3p Posterior mediastinal 6.3  3.2 (6) 3.4  1.7 (71) 0.0003
4 Tracheobronchial 7.1  3.7 (99) 4.4  2.3 (951) 0.0001
5 Botallo 6.9  4.0 (28) 4.1  2.1 (425) 0.0001
6 Para-aortic 7.5  7.1 (24) 3.8  1.9 (445) 0.0001
7 Subcarinal 7.2  3.9 (85) 4.3  2.2 (1246) 0.0001
8 Paraesophageal 8.5  3.6 (28) 4.0  1.8 (231) 0.0001
9 Pulmonary ligament 5.1  1.9 (18) 3.8  1.7 (189) 0.0026
Hilar lymph nodes
10 Hilar 7.0  3.3 (96) 4.5  2.0 (1248) 0.0001
11 Interlobar 6.7  3.3 (161) 4.4  2.0 (1571) 0.0001
12 Lobar 6.4  3.1 (87) 4.4  2.1 (813) 0.0001
Pulmonary lymph nodes
13 Segmental 4.5  1.9 (13) 3.8  1.8 (100) NS
14 Subsegmental 2.0 (1) 3.0  0 (2) —
Total 6.8  3.9 (844) 4.2  2.1 (10462) 0.0001
LN, lymph node; NS, not significance; —, not calculated.
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right upper lobe and 7 of the right lower lobe, whereas it was
1.14 to 4.00% in hilar stations: 10 of the right upper lobe, 10 of
the right lower lobe, and 10 of the left lower lobe (Table 3). This
table included patients who underwent a dissection of more than
three lymph nodes and mediastinal lymph node stations of each
lobe were selected based on the assumption that mediastinal
lymph node metastasis were dependent on the lobe9 and exis-
tence of a sentinel node.12,13
DISCUSSION
Generally, lymph nodes with metastasis of lung cancer
are enlarged its size, and preoperative clinical N-staging is
mainly defined by the findings of chest CT and, if necessary,
EUS-FNA and mediastinoscopy. There are many reports that
lymph nodes measuring 1 cm in size or larger on the CT
findings have an abnormal size and thus possibly indicating
metastasis of carcinoma14,15; however, the sensitivity and
specificity of CT are 69% and 71%, respectively.1 Recently,
general examinations tend to use PET/CT for staging; how-
ever, smaller lymph nodes with metastasis cannot be detected
by PET.16 This study analyzed the correlation between lymph
nodes with and without metastasis of lung cancer.
The lymph node size of the short-axis diameter of each
lymph node station is shown in Table 1. Mediastinal and hilar
lymph nodes with metastasis were significantly greater than
those without metastasis. Pulmonary lymph nodes with me-
tastasis of the segmental station also tended to be greater;
however, these stations (13 and 14) were not statistically
analyzed because of the small sample number. The short-axis
diameter of metastatic lymph node was 1.5 to 2 times greater
than nonmetastatic ones and the long-axis diameter showed
the same results. The determination of whether lymph nodes
did or did not have metastasis based on the findings of chest
CT was made using the short-axis diameter more frequently
than the long-axis diameter. It is occasionally impossible to
accurately judge the long-axis diameter because of variable
width CT in a horizontal slice. In addition, in our data, the
size of the nonmetastatic hilar lymph nodes was larger than
that of the nonmetastatic mediastinal lymph nodes. Generally,
normal lymph nodes of the N1 station are smaller than those
of the N2 station and usually the first nodes to become
involved. This might have biased the results. For instance, the
lymph node dissection occasionally might be difficult to
retain its original form. In that case, an accurate size might
not be able to be measured. The volume of the lymph nodes
is shown in Table 2. This result was as same for different
histologic examinations, except for LC; however, there was
an insufficient statistical power available to evaluate LC
because of the small sample size. The volume of the lymph
nodes with metastasis was significantly greater than without
metastasis, and this result was the same with each type of
histology. Furthermore, the characteristics of size of the
lymph nodes were analyzed with regard to the short-axis
diameter and the volume of AC and SQ by using an ROC
curve (Figure 1). When the short-axis diameters of 6 and 10
mm were used as cutoff values, the sensitivity and specificity
of SQ and AC were as follows: SQ, 67.2 and 79.5% at 6 mm,
30.7 and 95.8% at 10 mm, respectively; AC, 47.0 and 83.3%
at 6 mm, 18.6 and 97.3% at 10 mm, respectively (Figure 1).
According to these results, the lymph nodes were more
frequently metastatic with AC was than with SQ, even with
small-sized lymph nodes. However, it might be possible to
predict metastasis of SQ by its short-axis diameter. Further-
more, the volume was more sensitive than the short-axis
diameter (Figure 1B); when the volume of 200 mm3 was
defined as the cutoff value, the sensitivity and specificity of
SQ and AC were 72.8 and 69.8%, respectively (SQ), and 37.2
FIGURE 1. Receiver operating characteristic (ROC) curves
for the short-axis diameter (A) and the volume (B) of AC
(thin line) and SQ (thick line). AUCs of the short-axis diame-
ter of AC and SQ are 0.727 and 0.785, respectively, and
those of the volume of AC and SQ are 0.540 and 0.761, re-
spectively. AUC  the area under the ROC curve.
TABLE 2. Lymph Node Differentiation Classified with
Histology
Histology
Mean Volume (mm3)
Positive Metastasis (n) Negative Metastasis (n) p
AC 660.5  1727.6 (587) 194.6  377.2 (5833) 0.0001
BAC 0 (0) 187.5  475.4 (602) —
SQ 1489.4  3099.6 (192) 258.9  534.9 (3192) 0.0001
AC-SQ 1919.6  3817.6 (35) 240.4  515.9 (365) 0.0001
LC 2951.0  2420.0 (6) 406.4  721.2.9 (200) 0.0001
SCLC 1930.4  3189.4 (24) 231.5  540.6 (267) 0.0001
Total 968.1  2354.2 (844) 220.2  455.6 (10462) 0.0001
AC, adenocarcinoma; BAC, bronchioloalveolar carcinoma; SQ, squamous cell
carcinoma; AC-SQ, adenosquamous cell carcinoma; LC, large cell carcinoma; SCLC,
small cell lung cancer; —, not calculated.
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and 70.0%, respectively (AC). For example, a volume of 100
mm3 is the size of a coffee bean (7  5  5 mm), and 200
mm3 is the size of a soybean (9  7  6 mm). Therefore, a
size-guided lymph node sampling is roughly as adequate
accuracy as CT-scanning in encouraged.
The question remains regarding whether or not it is safe
to judge surgical staging, especially N stage, by lymph node
sampling during lung cancer surgery. The frequency of
lymph node metastasis was analyzed by ranking the size of
the lymph nodes with metastasis (Figure 2 and Table 3). The
patients with AC or SQ that had had six or more lymph nodes
dissected were included. Of these patients, 248 were with AC
and 123 with SQ. Figure 2 shows all of the dissected-lymph
nodes data, including the mediastinal, hilar, and pulmonary
lymph nodes. There was only a slight correlation with me-
tastasis according to the small size of lymph nodes; however,
the correlation of the lymph nodes with metastasis was much
higher if the lymph nodes were smaller than the fifth largest
lymph nodes: 16.1 to 26.2% in AC and 9.7 to 22.6% in SQ.
Some lymph nodes demonstrated metastasis in the third
largest or less even though the largest and second largest
lymph nodes had no metastasis: 6.0 to 11.3% in AC and 7.3
to 11.4% in SQ. In Table 3, each lymph node station associ-
ated with each lobe lymph flow was analyzed. According to this
data, there were metastatic lymph nodes in 1.87 to 3.03% of
mediastinal lymph node and 1.14 to 4.00% of hilar lymph node,
ranked by the lymph node volume. Ikeda et al.17 reported that a
mediastinal lymph node biopsy should sample not only the
largest but also second largest nodes because about 10% false-
negative results are obtained by only dissecting the largest
lymph nodes. However, in the current results, there was about a
2% risk of false-negative N staging even if both the largest and
FIGURE 2. Rank of the size of lymph nodes with metastasis in adenocarcinoma (AC) and squamous cell carcinoma (SQ). The
short-axis diameter with AC (white bar), the short-axis diameter (dot bar), the volume of lymph nodes with AC (black bar),
and the volume of lymph nodes with SQ (gray bar). 1st 2nd () 3rd () means that largest and second largest lymph
nodes had no metastasis, whereas the third largest lymph nodes or smaller ones did demonstrate metastasis.
TABLE 3. The Ratio of Mediastinal and Hilar Lymph Node
Stations with Metastasis in Each Lobe
Lobe
Mediastinal Lymph Node
Station
Hilar Lymph Node
Station
RUL 3 (n  107) 1.87% (2/107) 10 (n  88) 1.14% (1/88)
4 (n  66) 3.03% (2/66)
RML 3 (n  14) 0% 10 (n  9) 0%
7 (n  7) 0%
RLL 7 (n  49) 2.04% (1/49) 10 (n  47) 2.13% (1/47)
LUL 5 (n  42) 0% 10 (n  49) 0%
6 (n  44) 0%
LLL 7 (n  30) 0% 10 (n  25) 4.00% (1/25)
These data included the cases without metastasis of the largest and second largest
lymph nodes and with metastasis of third largest or less, and the size was classified with
the volume.
RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left
upper lobe; LLL, left lower lobe.
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second largest mediastinal lymph nodes were nonmetastatic.
Generally, hilar lymph nodes are simultaneously dissected dur-
ing a lobectomy. However, sampling only the largest and second
largest mediastinal lymph nodes would risk failing to treat N2
lung cancer in a small number of patients. Specifically, the risk
would be high in the stations of the right upper, right lower, and
left lower lobes. Lung cancer surgery should include the dissec-
tion of the systematic lymph nodes, including the mediastinal
lymph nodes.
This study showed that systematic lymph node dissec-
tion for lung cancer is necessary in pulmonary resections,
especially with patients with AC.
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